GYRE
Gyre Therapeutics Inc.
NASDAQ: GYRE · HEALTHCARE · BIOTECHNOLOGY
$4.30
+0.94% today
Updated 2026-11-12
Market cap
$470.79M
P/E ratio
—
P/S ratio
4.29x
EPS (TTM)
$-0.25
Dividend yield
—
52W range
$4 – $9
Volume
0.2M
Gyre Therapeutics Inc. (GYRE) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$4.30
12-Month target
$0.94
2030 Target
—
Intrinsic (DCF)
—
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.2B | $0.2B | $0.2B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 20.00% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -19.30%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.